ArticleNanoscale2017
Tissue factor-specific ultra-bright SERRS nanostars for Raman detection of pulmonary micrometastases.
Article in Nanoscale, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- pH-Dependent Silica Nanoshell Degradation Influences SERRS Enhancement in Biological Environments.ACS measurement science au · 2026Article
- Label-free streamlined photoacoustic image guidance facilitates NIR-II photoablation in models of melanoma lung metastases.The Journal of clinical investigation · 2026Article
- In vivo surface-enhanced Raman scattering techniques: nanoprobes, instrumentation, and applications.Light, science & applications · 2025Review
- High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles.Biomedical optics express · 2024Article
- Advancing Brain Research through Surface-Enhanced Raman Spectroscopy (SERS): Current Applications and Future Prospects.Biosensors · 2024Review
- Challenges and opportunities for SERS in the infrared: materials and methods.Nanoscale advances · 2023Review
- Multiplexed molecular imaging with surface enhanced resonance Raman scattering nanoprobes reveals immunotherapy response in miceNanoscale horizons · 2022Article
- Multiplexed imaging in oncology.Nature biomedical engineering · 2022Review
- Visualizing surface marker expression and intratumoral heterogeneity with SERRS-NPs imaging.Nanotheranostics · 2022Article
- Design and synthesis of gold nanostars-based SERS nanotags for bioimaging applications.Nanotheranostics · 2022Review
- Advances in Surface Enhanced Raman Spectroscopy forNanotheranostics · 2022Review
- Functional Characteristics and Regulated Expression of Alternatively Spliced Tissue Factor: An Update.Cancers · 2021Review
- AccurateTheranostics · 2021Article
- Image-guided tumor surgery: The emerging role of nanotechnology.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Ultrabright gap-enhanced Raman tags for high-speed bioimaging.Nature communications · 2019Article
- DNA-enabled rational design of fluorescence-Raman bimodal nanoprobes for cancer imaging and therapy.Nature communications · 2019Article
- Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting.Journal of visualized experiments : JoVE · 2019Article
- Non-invasiveTheranostics · 2019Article
- Emergence of two near-infrared windows for in vivo and intraoperative SERS.Current opinion in chemical biology · 2018Review
- MUC1 Aptamer Targeted SERS Nanoprobes.Advanced functional materials · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Here we demonstrate a novel application of 'surface enhanced resonance Raman scattering nanoparticles' (SERRS NPs) for imaging breast cancer lung metastases with much higher precision than currently feasible. A breast cancer lung metastasis mouse model was established by intravenous injection of LM2 cells. These mice were intravenously administered SERRS NPs conjugated with ALT-836, an anti-tissue factor (TF) monoclonal antibody, and subjected to Raman imaging to visualize the expression of TF both in vivo and ex vivo. Raman imaging indicated marked uptake of αTF-SERRS-NPs by the lung metastases compared to isotype and blocking controls. Conversely, little uptake of αTF-SERRS-NPs was observed in the lungs of healthy mice. Successful detection and delineation of pulmonary micrometastatic lesions as small as 200 μm, corroborated by histology, immunohistochemistry, and bioluminescence imaging confirmed the suitability of both TF as a target and αTF-SERRS-NPs as an effective contrast agent for imaging breast cancer lung metastases. Further advancements of this technique in the form of Raman endoscopes coupled with ultrabright SERRS NPs developed in this work could lead to minimally invasive detection and resection of lung metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.